Consolidated statement of cash flows
January 1 – December 31
millions of CHF |
|
|
2023 |
|
2022 |
|
|
Cash and cash equivalents as of January 1 |
|
|
313.5 |
|
209.8 |
|
|
|
|
|
|
|
|
|
|
Net income |
|
|
|
0.7 |
|
11.6 |
|
Loss on net assets derecognized and retained investment |
|
|
– |
|
15.4 |
|
|
Interest income |
|
|
–1.3 |
|
–0.7 |
|
|
Interest expenses |
|
|
10.0 |
|
6.5 |
|
|
Income tax expenses |
|
|
2.2 |
|
0.6 |
|
|
Depreciation, amortization and impairments |
|
|
58.4 |
|
51.1 |
|
|
(Gains) / losses from disposals of tangible and intangible assets |
|
|
0.0 |
|
0.0 |
|
|
Changes in inventory |
|
|
|
1.2 |
|
–30.5 |
|
Changes in advance payments to suppliers |
|
|
|
–0.8 |
|
1.3 |
|
Changes in contract assets |
|
|
|
–0.3 |
|
–1.0 |
|
Changes in trade accounts receivable |
|
|
|
2.3 |
|
–37.9 |
|
Changes in contract liabilities |
|
|
|
0.2 |
|
–0.3 |
|
Changes in trade accounts payable |
|
|
|
–3.3 |
|
10.0 |
|
Changes in employee benefit plans |
|
|
|
–0.1 |
|
–5.9 |
|
Changes in provisions |
|
|
|
5.7 |
|
–1.0 |
|
Changes in other net current assets |
|
|
|
–6.7 |
|
17.7 |
|
Other non-cash items |
|
|
|
0.7 |
|
27.1 |
|
Interest received |
|
|
|
1.3 |
|
0.6 |
|
Interest paid |
|
|
|
–6.3 |
|
–6.5 |
|
Income tax paid |
|
|
|
–7.9 |
|
–10.5 |
|
Total cash flow from operating activities |
|
|
|
56.1 |
|
47.6 |
|
|
|
|
|
|
|
|
|
Purchase of intangible assets |
|
|
–6.5 |
|
–2.2 |
|
|
Purchase of property, plant and equipment |
|
|
|
–46.4 |
|
–36.4 |
|
Sale of property, plant and equipment |
|
|
0.2 |
|
1.3 |
|
|
Cash consideration for acquisitions, net of cash acquired |
|
|
–29.4 |
|
–14.7 |
|
|
Deconsolidation of medmix Poland, cash derecognized |
|
|
– |
|
–2.0 |
|
|
Acquisitions of associates |
|
|
–5.7 |
|
– |
|
|
Divestitures of investments in subsidiaries |
|
|
|
4.0 |
|
– |
|
Sale of other non-current financial assets |
|
|
|
– |
|
0.1 |
|
Purchase of current financial assets |
|
|
|
– |
|
–3.3 |
|
Sale of current financial assets |
|
|
|
3.3 |
|
0.2 |
|
Total cash flow from investing activities |
|
|
|
–80.6 |
|
–57.0 |
|
|
|
|
|
|
|
|
|
Dividends paid to shareholders |
|
|
–15.0 |
|
–15.0 |
|
|
Dividends paid to non-controlling interests in subsidiaries |
|
|
|
–1.3 |
|
– |
|
Purchase of treasury shares |
|
|
–3.1 |
|
–6.1 |
|
|
Payments of lease liabilities |
|
|
–10.4 |
|
–8.9 |
|
|
Transaction costs related to loans and borrowings |
|
|
|
–0.4 |
|
– |
|
Repayments of non-current borrowings |
|
|
– |
|
–3.0 |
|
|
Proceeds from current borrowings |
|
|
33.6 |
|
310.5 |
|
|
Repayments of current borrowings |
|
|
–157.2 |
|
–161.6 |
|
|
Total cash flow from financing activities |
|
|
|
–153.8 |
|
116.1 |
|
|
|
|
|
|
|
|
|
Exchange gains / (losses) on cash and cash equivalents |
|
|
|
–4.6 |
|
–2.9 |
|
|
|
|
|
|
|
|
|
Net change in cash and cash equivalents |
|
|
|
–182.9 |
|
103.7 |
|
|
|
|
|
|
|
|
|
Cash and cash equivalents as of December 31 |
|
|
130.6 |
|
313.5 |
|
For the calculation of free cash flow (FCF), reference is made to the section financial review.